Skip to main content
. 2012 Feb 17;104(6):461–475. doi: 10.1093/jnci/djs009

Figure 3.

Figure 3

Ang2-blocking antibodies inhibit primary tumor growth, angiogenesis, and lymphangiogenesis. A) Growth curves of LNM35 primary tumors in nu/nu mice treated with the Ang2-blocking antibodies or hIgG control, n = 8 in both groups. One-way analysis of variance. B) Tumor weights at excision 16 days after implantation, P = .002. Student's t test. C) Representative immunohistochemical images of LYVE-1- and CD31-stained tumor sections. D) Quantification of densities and area fractions of Lyve-1-positive lymphatic vessels and of CD31-positive blood vessels from at least five histological sections, P = .013 and .019, respectively. Student's t test. All statistical tests were two-sided. *P < .05. Error bars = 95% CI. Anti-Ang2 = angiopoietin-2-blocking antibody; CD31 = cluster of differentiation 31; hIgG = human immunoglobulin G; LYVE-1 = lymphatic vessel endothelial hyaluronan receptor-1. Scale bar, 120 μm.